ABVC Abvc Biopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ABVC

Price (delayed)

$0.9594

Market cap

$25.57M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.29

Enterprise value

$28.16M

?
Relative Growth: Rel. Growth: 9
Relative Strength: Rel. Strength: 6
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 4

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process at world-famous research institutions ...

Highlights
ABVC's net income has dropped by 68% year-on-year but it is up by 18% since the previous quarter
The debt has soared by 65% YoY but it has contracted by 4% from the previous quarter
The gross profit has dropped by 100% year-on-year
The revenue has dropped by 100% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ambrivis.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of ABVC

ABVC stock price

How has the Abvc Biopharma stock price performed over time
Intraday
-0.07%
1 week
-5.94%
1 month
-28.93%
1 year
-67.7%
YTD
-54.96%
QTD
-39.28%

Financial performance

How have Abvc Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$6.52M
Net income
-$7.11M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% year-on-year
The revenue has dropped by 100% year-on-year
ABVC's net income has dropped by 68% year-on-year but it is up by 18% since the previous quarter
ABVC's operating income has shrunk by 63% YoY but it is up by 19% QoQ

Price vs fundamentals

How does ABVC's price correlate with its fundamentals

Growth

What is Abvc Biopharma's growth rate over time

Valuation

What is Abvc Biopharma stock price valuation
P/E
N/A
P/B
2.42
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Abvc Biopharma's EPS has increased by 26% QoQ but it has decreased by 7% YoY
The P/B is 53% less than the 5-year quarterly average of 5.1 and 42% less than the last 4 quarters average of 4.2
ABVC's equity is up by 47% year-on-year but it is down by 4.5% since the previous quarter
The revenue has dropped by 100% year-on-year

Efficiency

How efficient is Abvc Biopharma business performance
ABVC's ROIC is up by 25% QoQ
The company's return on equity rose by 24% QoQ and by 16% YoY
The ROA has grown by 21% since the previous quarter but it has declined by 10% year-on-year

Dividends

What is ABVC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABVC.

Financial health

How did Abvc Biopharma financials performed over time
ABVC's total assets is 172% greater than its total liabilities
The quick ratio has dropped by 87% year-on-year and by 29% since the previous quarter
ABVC's current ratio has dropped by 83% year-on-year and by 42% since the previous quarter
The debt is 75% less than the equity
The debt has soared by 65% YoY but it has contracted by 4% from the previous quarter
ABVC's equity is up by 47% year-on-year but it is down by 4.5% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.